Login E-loket

The European Partnership for Personalised Medicine (EP PerMed) – Horizon Europe cofund partnership

Personalised medicine research.

Status

“Personalised Medicine for CARdiovascular, MEtabolic, and KidNey diseases (CARMEN2026)”

On the 25th of November 2025 a new joint transnational cofunded call for research projects has been launched within the framework of the Horizon Europe personalised medicine partnership. This partnership initiates a range of activities, of which launching calls for research projects form an integral part. The FWO, in its capacity as research funder, engages itself within the research calls of this partnership, in order to support the universities and public research institutes from Flanders.

EP PerMed call 2026

Within this new transnational call the EP PerMed will fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects:

  • Development and validation of innovative personalised therapeutic approaches for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or in silico models).
  • Identification and validation of molecular markers/signatures or cutting-edge technologies to monitor treatment response in patients with cardiovascular, metabolic or kidney diseases in order to tailor treatment pathways. This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.
  • Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologies for early disease risk prediction and prevention of disease worsening or comorbidities in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.

Submission

Deadline for pre-proposal submission AND national pre-application via the FWO e-loket

10 February 2026, 14.00 CET (Brussels)

FWO-modalities

Both the national/regional FWO fundamental (FO) and Strategic Basic Research (SBO) funding channels are integrated within this multilateral call. The type and scope of the proposed research project will determine the choice of funding channel for the research performed within Flanders (e.g. more fundamental in nature, or more aimed at economical/societal valorisation). Non-compliance with the specific requirements per funding channel might lead to non-eligibility.

Please note, this is only an FWO requirement: European and/or international partners within the project consortium can choose their type of research freely, according to their own national regulations.

For the fundamental funding channel the respective regulations apply. For the SBO channel the SBO regulations have to be taken into account: these imply projects with a primarily economic and/or societal finality, for which ‘valorisation’ is a key - and mandatory - aspect.

Submission

Project proposals have to be submitted by European and international consortia through the ‘EP PerMed’ call secretariat, by making use of the designated pre-proposal template and submission platform, according to the applicable procedures and eligibility criteria included in the call documents and regulations mentioned above. There is also the possibility of using a partnering tool, which helps researchers with identifying potential consortium partners.

In case the consortium includes more than one partner requesting funding from FWO, a single online form should be submitted containing all relevant information from the different Flemish partners.

The deadline to submit the administrative application to the FWO is the same as the deadline of the joint transnational call (preproposal stage). To ensure the eligibility of the proposal, it is recommended to consult the FWO administration at least one week in advance.

Call budget

The FWO is able to support two projects for a 36 months duration, with an available maximum budget of 350.000 EUR (overhead included) per project/consortium. The FWO budgetary rules, which differ per funding channel, are also clarified in the Guidelines for applicants’ document (from p. 24 onwards).

The cofund partnerships under the Horizon Europe framework programme provide for co-financing by the European Commission in addition to national/regional funds. This can result in additional support at the time of the funding decision, based on the final ranking after international peer review, which can generate additional projects – also for Flanders.

Key points and deviations from the ‘regular’ FWO participatory framework

Some key points and deviations from the ‘regular’ FWO participatory framework to consider:

  • Participation in the framework of the European co-funded partnerships does not interfere with the ‘regular/national’ FWO project submission framework, and is consequently not taken into account with regard to the max. available number of applications that can be applied for/run. However, researchers can only participate in a maximum of two different international consortia per call, provided they concern different subjects.
  • Diverging overhead arrangements apply for what the fundamental and SBO funding channels are concerned, which is clarified in the Guidelines for applicants’ document (from p. 24 onwards).
  • SBO projects aimed at developing a spin-off are not eligible in this context. As such, no mention of this option should be made in the FWO pre-registration document.
  • Projects have a max. duration of 36 months and should be budgeted accordingly. Automatic extensions/no-cost prolongations are not accepted in this framework. Consequently, article 28 of the FWO research project regulations and article 14 of the SBO project regulations are explicitly excluded.
  • The PI, for each of the participating institutions from Flanders, must hold an admissible appointment that fully covers the duration of the research project. With regard to the ‘FO’ projects, and more specifically regarding the ‘emeritus’ regulation (artikel 10, §7): it does not apply in this context.
  • In essence the FWO funds pre-clinical research.
  • Research teams applying for funding from the FWO may involve ‘stakeholders’ (e.g. patient organisations, interest groups, public and/or private organisations) as subcontractors in a research project, including for non-routine tasks. Contact the FWO for further information if needed.

Researchers are strongly advised to contact the FWO before submission regarding the eligibility criteria. This to avoid the ineligibility of a researcher individually, and the project consortium as a whole.

Contact

For additional information FWO participation, please contact:

Toon Monbaliu (General and ‘FO’)

europe@fwo.be  

+32 (02)2 550 15 70

Kristien Peeters (‘SBO’)

europe@fwo.be

+32 (0)2 550 15 95